Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1950
Gene Symbol: EGF
EGF
0.100 Biomarker phenotype BEFREE These results suggest that EGF and TPA may share only 1 class of receptors, and that TPA may be used to monitor cancer progression. 6118206 1981
Entrez Id: 7039
Gene Symbol: TGFA
TGFA
0.100 Biomarker phenotype BEFREE The possibility is raised that TGF-alpha might contribute to tumor progression in these cases of Burkitt's lymphoma. 3863708 1985
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.070 AlteredExpression phenotype BEFREE These data suggest that elevation of p21ras may be a common event in early stages of colon tumors, and tumor progression may lead to a more autonomous population of cells in which other growth factors supplant the role of this protein. 3885218 1985
Entrez Id: 79801
Gene Symbol: SHCBP1
SHCBP1
0.040 Biomarker phenotype BEFREE PAL-M1 and PAL-M2 may be immunohistochemical markers for tumor progression in melanocytic proliferations. 3891875 1985
Entrez Id: 5066
Gene Symbol: PAM
PAM
0.010 Biomarker phenotype BEFREE PAL-M1 and PAL-M2 may be immunohistochemical markers for tumor progression in melanocytic proliferations. 3891875 1985
Entrez Id: 26103
Gene Symbol: LRIT1
LRIT1
0.010 Biomarker phenotype BEFREE PAL-M1 and PAL-M2 may be immunohistochemical markers for tumor progression in melanocytic proliferations. 3891875 1985
Entrez Id: 6497
Gene Symbol: SKI
SKI
0.050 Biomarker phenotype BEFREE Further analysis of the chromosome breaks in this group of lymphomas suggested that those involving the SKI site probably are of importance in tumor progression. 3026737 1986
Entrez Id: 5894
Gene Symbol: RAF1
RAF1
0.100 Biomarker phenotype BEFREE The rearrangement of c-raf-1 may have occurred during transfection or may have been present in a small population of the original tumor cells as a result of tumor progression. 3299054 1987
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression phenotype BEFREE This small but extensively studied group of cases has indicated that increased c-erbB-2 protein can be identified routinely in fixed tissue sections, making it possible to carry out extensive studies to look for clinical correlates, but also to assess the stage in tumour progression at which the increased expression occurs and whether it correlates with any potentially premalignant condition. 3330998 1987
Entrez Id: 6037
Gene Symbol: RNASE3
RNASE3
0.020 Biomarker phenotype BEFREE The rearrangement of c-raf-1 may have occurred during transfection or may have been present in a small population of the original tumor cells as a result of tumor progression. 3299054 1987
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.070 AlteredExpression phenotype BEFREE Expression of v-Ha-ras in biochemical variant SCLC cells directly demonstrates that important transitions can occur between phenotypes of human lung cancer cells and that these may play a critical role in tumor progression events in patients. 2842776 1988
Entrez Id: 967
Gene Symbol: CD63
CD63
0.050 AlteredExpression phenotype BEFREE The melanoma-associated antigen ME491 is expressed strongly during the early stages of tumor progression. 3365686 1988
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression phenotype BEFREE Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. 2571966 1989
Entrez Id: 4609
Gene Symbol: MYC
MYC
0.100 Biomarker phenotype BEFREE This finding implies independent amplification events and supports the idea that the amplification of myc genes is probably a secondary event correlated with tumor progression. 2545636 1989
Entrez Id: 4893
Gene Symbol: NRAS
NRAS
0.090 GeneticVariation phenotype BEFREE Each example of an activated ras gene showed a mutation at the 61st codon of the protein, with the exception of one melanoma which showed a mutation at codon 13 of the N-ras gene; (2) all the melanomas displaying an activated ras gene had a similar cell surface phenotype and appear to come from a similar phase of differentiation; (3) 5-6% of noncultured primary and metastatic melanomas have mutated ras genes; (4) no ras gene mutations were found in any precursor lesion, specifically normal nevi and dysplastic nevi; (5) immunoperoxidase analysis of paraffin-embedded specimens indicated no quantitative or qualitative alterations in p21 expression that correlate with tumor progression; (6) there were no observable differences in p21 expression between melanoma cells growing exponentially or in plateau phase, or between melanoma cells with or without ras mutations; nor were any cell kinetic differences found between cells with and without mutated ras genes. 2682463 1989
Entrez Id: 4162
Gene Symbol: MCAM
MCAM
0.070 Biomarker phenotype BEFREE MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. 2602381 1989
Entrez Id: 3105
Gene Symbol: HLA-A
HLA-A
0.030 Biomarker phenotype BEFREE Because a loss of tumor cell HLA-A,B,C antigen or lymphocyte function-associated antigen 3 could be selected for through an advantage in escape from cytotoxic T-lymphocyte attack, our results suggest that immunoselection may be a more important mechanism in tumor progression than has previously been assumed. 2473473 1989
Entrez Id: 8661
Gene Symbol: EIF3A
EIF3A
0.030 AlteredExpression phenotype BEFREE Increased expression of this putative growth factor receptor has been reported to occur by molecular mechanism other than gene amplification and for this reason we have studied the expression of the p185 protein in normal colon and in lesions representing different stages of neoplastic progression. 2571966 1989
Entrez Id: 965
Gene Symbol: CD58
CD58
0.010 Biomarker phenotype BEFREE Because a loss of tumor cell HLA-A,B,C antigen or lymphocyte function-associated antigen 3 could be selected for through an advantage in escape from cytotoxic T-lymphocyte attack, our results suggest that immunoselection may be a more important mechanism in tumor progression than has previously been assumed. 2473473 1989
Entrez Id: 100188830
Gene Symbol: AD12
AD12
0.010 Biomarker phenotype BEFREE Ad12-SV40-transformed human melanocytes and nevus cells are useful tools for studying tumor progression under experimental conditions. 2558080 1989
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE One patient with follicular small cleaved cell NHL that evolved to a small noncleaved cell NHL had coexisting bcl-2 and c-myc rearrangement in the aspiration specimen of the high-grade NHL, suggesting sequential bcl-2 and c-myc activation during the tumor's progression. 2189291 1990
Entrez Id: 4609
Gene Symbol: MYC
MYC
0.100 AlteredExpression phenotype BEFREE This in vivo rearrangement of the c-myc gene specific to tumor cells may represent one mechanism of activation of a protooncogene during tumorigenesis or tumor progression in human cancer. 2334929 1990
Entrez Id: 2919
Gene Symbol: CXCL1
CXCL1
0.100 AlteredExpression phenotype BEFREE In contrast, MGSA mRNA was constitutively expressed in the absence of exogenous growth factors in cultures established from benign intradermal and dysplastic nevi and melanoma lesions in different stages of tumor progression. 2095366 1990
Entrez Id: 23158
Gene Symbol: TBC1D9
TBC1D9
0.100 AlteredExpression phenotype BEFREE No correlation was found between MDR1 or N-myc genes expression and tumor progression. 1974410 1990
Entrez Id: 5243
Gene Symbol: ABCB1
ABCB1
0.100 AlteredExpression phenotype BEFREE No correlation was found between MDR1 or N-myc genes expression and tumor progression. 1974410 1990